Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP

Abstract

Summary Nitrogen‐containing bisphosphonates indirectly activate Vγ9Vδ2 T cells through inhibition of farnesyl pyrophosphate synthase and intracellular accumulation of isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), but the cells responsible for Vγ9Vδ2 T cell activation through IPP/DMAPP accumulation are unknown. Treatment of human peripheral blood mononuclear cells (PBMCs) with a pharmacologically relevant concentration of zoledronic acid induced accumulation of IPP/DMAPP selectively in monocytes, which correlated with efficient drug uptake by these cells. Furthermore, zoledronic acid‐pulsed monocytes triggered activation of γδ T cells in a cell contact‐dependent manner. These observations identify monocytes as the cell type directly affected by bisphosphonates responsible for Vγ9Vδ2 T cell activation.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 12

1. 1.

   Bonneville M, Scotet E. Human Vγ9Vδ2 T cells: promising new leads for immunotherapy of infections and tumors. Current Opinion in Immunology. 2006;18:539-546.

   Not in our library10.1016/j.coi.2006.07.002

2. 2.

   Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. Journal of Clinical Pharmacology. 2002;42:1228-1236.

   Not in our library10.1177/009127002762491316

3. 3.

   Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. Journal of Experimental Medicine. 2003;197:163-168.

   Not in our library10.1084/jem.20021500

4. 4.

   Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins. Clinical and Experimental Immunology. 2005;139:101-111.

   Not in our library10.1111/j.1365-2249.2005.02665.x

5. 5.

   Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384-392.

   Not in our library

6. 6.

   Legay F, Gauron S, Deckert F, Gosset G, Pfaar U, Ravera C, Wiegand H, Schran H. Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 2002;30:897-911.

   Not in our library10.1016/s0731-7085(02)00218-2

7. 7.

   Miyagawa F, Tanaka Y, Yamashita S, Minato N. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. Journal of Immunology. 2001;166:5508-5514.

   Not in our library10.4049/jimmunol.166.9.5508

8. 8.

   Mönkkönen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsäläinen J, Mönkkönen JA. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. British Journal of Pharmacology. 2006;147:437-445.

   Not in our library10.1038/sj.bjp.0706628

9. 9.

   Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature. 1995;375:155-158.

   Not in our library10.1038/375155a0

10. 10.

    Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma delta-T-cell proliferation and activation in vitro. Journal of Bone and Mineral Research. 2004;19:278-288.

    Not in our library10.1359/jbmr.0301230

11. 11.

    Thompson K, Rojas-Navea J, Rogers MJ. Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway. Blood. 2006a;107:651-654.

    Not in our library10.1182/blood-2005-03-1025

12. 12.

    Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Molecular Pharmacology. 2006b;69:1624-1632.

    Not in our library10.1124/mol.105.020776

Cited by papers we hold 10

• Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate Vγ9Vδ2 T cells · 2023
  No notice
• Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma · 2022
  No notice
• Monocyte-dependent co-stimulation of cytokine induction in human γδ T cells by TLR8 RNA ligands · 2021
  Not checked
• Cancer immunotherapy with γδ T cells: many paths ahead of us · 2020
  Corrected
• Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer · 2020
  No notice
• Interleukin-18 in Health and Disease · 2019
  No notice
• Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer · 2018
  No notice
• Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells · 2016
  No notice
• Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats · 2010
  No notice
• Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo · 2010
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.